6108.HK – New Ray Medicine International Holding Limited

Last Day

Pharmaceutical Retailers

• Trailing PE:
• Forward PE:
• Price Sales TTM:
• Price Book MRQ:
• Enterprise Value:
• Enterprise Value Revenue:
• Enterprise Value Ebitda:
• Beta:

• Shares Outstanding:
• Market Capitalization:
• Market Capitalization Mln:
• EBITDA:
• PE Ratio:
• PEG Ratio:
• Wall Street Target Price:
• Book Value:
• Dividend Share:
• Dividend Yield:
• Earnings Share:
• EPS Estimate Current Year:
• EPS Estimate Next Year:
• EPS Estimate Next Quarter:
• EPS Estimate Current Quarter:
• Most Recent Quarter:
• Profit Margin:
• Operating Margin TTM:
• Return On Assets TTM:
• Return On Equity TTM:
• Revenue TTM:
• Revenue Per Share TTM:
• Quarterly Revenue Growth YOY:
• Gross Profit TTM:
• Diluted Eps TTM:
• Quarterly Earnings Growth YOY:

• Type:
• Name:
• Exchange:
• Currency Code:
• Currency Name:
• Currency Symbol:
• Country Name:
• Fiscal Year End:
• IPO Date:
• International Domestic:
• Sector:
• Industry:
• Address:
• Country:
• Listings:
• Web URL:
• Full Time Employees:
• Updated At:
• Gic Sector:
• Gic Group:
• Gic Industry:
• Gic SubIndustry:

New Ray Medicine International Holding Limited, an investment holding company, engages in distribution and trading of injection drugs and pharmaceutical products in the People’s Republic of China. The company’s pharmaceutical products include injections, capsules, tablets, and other drugs for the treatment of muscular dystrophy, cardiomyopathy, acute and chronic myocardial infraction, angina pectoris, parenteral nutrition, hepatitis and impaired immunity, HBe antiogen-positive, decompensated liver cirrhosis, severe hepatitis, tumor relating hepatitis B and chronic hepatitis C, respiratory tract infections, urinary tract infections, genitourinary system infections, intra-abdominal infections, bone and joint infections, septicemia, catabolism, hypermetabolism, pneumonia, skin and soft tissue infections, pelvic inflammatory, diarrhea and digestive system relevant illness, biliary tract infection, and other infections. It also offers marketing and promotion services of drugs. The company was founded in 2001 and is headquartered in Hangzhou, the People’s Republic of China. Address: Dikai International Center, Hangzhou, China

The data, information and layout displayed above cannot be used for commercial purpose. We do not accept any liability for reliance of the information above. We can provide detailed description of source data regarding our industry research and valuation research to our clients upon request.